[{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Hypera Pharma","pharmaFlowCategory":"D","amount":"$825.0 million","upfrontCash":"Undisclosed","newsHeadline":"Takeda agrees to divest select OTC and Non core assets in Latin America to Hypera Pharma for $825 million USD","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Divestment","leadProduct":"Caffeine","moa":"Adenosine receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0.82999999999999996,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.82999999999999996,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Hypera S.A.","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Galt Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Opioid-free Pain Med Orphengesic Forte by Galt Pharmaceuticals Approved by FDA","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Orphenadrine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Galt Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Galt Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Galt Pharm.."},{"orgOrder":0,"company":"DSE Healthcare Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DSE Healthcare's VANQUISH Introduces Digital Headache Brand Pain Reliever For Modern Day Headaches","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Paracetamol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"DSE Healthcare Solutions","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"DSE Healthcare Solutions \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"DSE Health.."},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Strides Receives USFDA Approval for Butalbital, Acetaminophen, and Caffeine Tablets","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Butalbital","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Strides Pharma Science","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Strides Pharma Science \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Strides Ph.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Hypera Pharma","pharmaFlowCategory":"D","amount":"$825.0 million","upfrontCash":"Undisclosed","newsHeadline":"Takeda Completes Sale of Select OTC and Non-Core Assets to Hypera Pharma","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Divestment","leadProduct":"Caffeine","moa":"Adenosine receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0.82999999999999996,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.82999999999999996,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Hypera Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Granules India Limited Announces Approval of Acetaminophen, Aspirin and Caffeine Tablets","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Paracetamol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Granules India Limited","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Granules India Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Granules I.."},{"orgOrder":0,"company":"Seton Pharmaceuticals","sponsor":"Senores Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seton Pharmaceuticals, LLC and Senores Pharmaceuticals, Inc. Launch Butalbital, Acetaminophen and Caffeine Capsules USP, 50 mg\/325 mg\/40 mg in the U.S. Market","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Butalbital","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Seton Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Seton Pharmaceuticals \/ Senores Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Seton Phar.."},{"orgOrder":0,"company":"Comera Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Comera Life Sciences to Present Topline Results of SEQURUS-2 Study at 14th Annual Bioprocessing Summit","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Ipilimumab","moa":"CTLA-4","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Comera Life Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Comera Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Comera Lif.."},{"orgOrder":0,"company":"SkinMedica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SkinMedica\u00ae Launches Firm & Tone Lotion for Body","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Caffeine","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"SkinMedica","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Cream","sponsorNew":"SkinMedica \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"SkinMedica.."},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SkinMedica\u00ae Launches Even & Correct","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Caffeine","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Allergan Aesthetics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Cream","sponsorNew":"Allergan Aesthetics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Allergan A.."},{"orgOrder":0,"company":"Comera Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Comera Life Sciences Announces Favorable Preclinical Topline Safety Results of Lead SQore Excipient","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Caffeine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Comera Life Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Comera Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Comera Lif.."},{"orgOrder":0,"company":"Famar","sponsor":"LaviPharm","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"New Collaboration Between FAMAR and Lavipharm: Joining Forces in the Production of Pharmaceutical Products","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Collaboration","leadProduct":"Paracetamol","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Famar","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Famar \/ Lavipharm","highestDevelopmentStatusID":"12","companyTruncated":"Famar \/ La.."},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Strides Receives USFDA Approval for Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Butalbital","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Strides Pharma Science","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Strides Pharma Science \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Strides Ph.."},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Granules India Limited Announces Approval of Butalbital, Acetaminophen and Caffeine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Butalbital","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Granules India Limited","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"Granules India Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Granules I.."}]
Find Clinical Drug Pipeline Developments & Deals for Tox21_300010
Details :
Under the collaboration, FAMAR will undertake the production of two pharmaceutical products recently added to Lavipharm’s portfolio of analgesic pharmaceutical products, Lonarid N (paracetamol) and Lonalgal (caffeine Anhydrous).
Details :
The SkinMedica (coffea arabica) Even & Correct products are hydroquinone-free, well tolerated, and effective on all skin types and for multiple ethnicities. Most SkinMedica® products are intended to meet the FDA's definition of a cosmetic product.
Brand Name : SkinMedica
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 17, 2023
Lead Product(s) :
Coffea Arabica,Caffeine,Hydrolyzed Rice Protein
Details :
The US Food & Drug Administration (US FDA) has approved Abbreviated New Drug Application (ANDA) for Acetaminophen, Aspirin and Caffeine Tablets USP, 250 mg/250 mg/65 mg (OTC).
Brand Name : Acetaminophen/Aspirin/Caffeine-Generic
Details :
Strides Pharma has received approval for Butalbital, Acetaminophen, and Caffeine Tablets USP, 50 mg/325 mg/40 mg from the U.S Food & Drug Administration. The product is indicated for the relief of the symptom complex of tension (or muscle contraction) he...
Details :
USFDA approved generic version of Butalbital, Acetaminophen, Caffeine with Codeine Phosphate Capsules which is indicated for the relief of the symptom complex of tension headache (migraine).
Details :
USFDA approved generic version of Butalbital, Acetaminophen, Caffeine Capsules which is indicated for the relief of the symptom complex of tension headache (migraine).
Details :
SkinMedica® Firm & Tone Lotion for Body is a luxurious formula rooted in science that delivers transformative results. It is clinically proven to diminish the look of crepey skin, address uneven skin texture, improve the appearance of skin and tone, and...
Brand Name : SkinMedica
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 31, 2022
Lead Product(s) :
Coffea Arabica,Caffeine,Hydrolyzed Rice Protein
Details :
Comera announced favorable topline results of its SEQURUS-1 preclinical study in July, demonstrating supportive evidence of the safety of Comera’s lead caffeine-based proprietary SQore excipient when administered as a SQ biologic drug product formulati...
Details :
SQore is a caffeine-based excipient when administered as a subcutaneous and combination ipilimumab, a mAb therapy that works to activate the immune system by targeting CTLA-4 to treat melanoma, as a model protein.
Details :
Butalbital, Acetaminophen and Caffeine Capsules USP, 50 mg/325 mg/40 mg, a therapeutic equivalent of reference listed drug Butalbital, Acetaminophen, and Caffeine capsules of Mayne Pharma, indicated for relief of symptom complex of tension (or muscle con...